EUVIMEDEUVIMED entdecken
Fallbericht

Dual prostacyclin infusions: A case report of a patient symptom–driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension

Jessica N Stone, Dalton J Kuebel iD, Maria R Guido iD, Jean M Elwing iD, Arun Jose iD

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxae290 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Jessica N Stone und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, The University of Kansas Health System, Kansas City, KS, USA. Hauptthemen laut MEDLINE: Epoprostenol, Antihypertensive Agents, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A case of successful transition from high-dose epoprostenol to high-dose subcutaneous treprostinil for treatment of pulmonary arterial hypertension (PAH) is reported. Summary PAH is a chronically progressive disease characterized by pulmonary artery luminal narrowing that causes increased pulmonary artery pressures leading to right ventricular failure. Parenteral prostacyclin analogues, such as epoprostenol and treprostinil, are direct vasodilators and are cornerstones of therapy for patients with severe disease that have been proven to reduce mortality and increase exercise tolerance. These agents must be administered continuously via intravenous or subcutaneous devices and are high-risk medications due to their potent vasodilatory actions. Chronic use of these medications requires constant attention from both providers and patients because of potential complications including central venous catheter infection, thromboembolism, therapy interruptions, and other undesirable consequences. This case report describes management of a 35-year-old male patient on high-dose outpatient intravenous epoprostenol (101 ng/kg/min; dosing weight, 47 kg) for treatment of PAH who was admitted to the hospital with a malfunctioning central venous catheter. Surrounding manipulation of the central catheter, the patient experienced an ischemic stroke that led to cognitive disability resulting in a lack of ability to manage his previously used home infusion device. The patient was successfully transitioned from intravenous epoprostenol to subcutaneous treprostinil (discharge dose, 200 ng/kg/min) over 5 days by infusing both medications simultaneously and adjusting doses based upon patient-reported symptoms.

Conclusion

This successful transition from high-dose epoprostenol to high-dose subcutaneous treprostinil demonstrates the importance in considering patient-specific factors during high-risk medication transitions, the value of a patient-directed flexible prostacyclin transition plan, and the benefit of institutional training and education in ensuring the safe use of parenteral prostacyclin analogues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpoprostenolAntihypertensive AgentsPulmonary Arterial HypertensionHypertension, PulmonaryHumansMaleAdultInfusions, SubcutaneousInfusions, Intravenous

Stichwörter der Autor:innen

epoprostenolmedication transitionpatient-drivenprostacyclinpulmonary arterial hypertensiontreprostinil

Substanzen

EpoprostenoltreprostinilAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Pharmacy Services, The University of Kansas Health System, Kansas City, KS, USA.
  • Department of Pharmacy Services, UC Health - University of Cincinnati Medical Center, Cincinnati, OH.
  • Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH, USA.
  • Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH.
  • Pharmacy Administration, UC Health, Cincinnati, OH, USA.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, OH, USA.

ORCID-Profile: Dalton J Kuebel, Maria R Guido, Jean M Elwing, Arun Jose

Zitieren

APA

Stone, J. N., Kuebel, D. J., Guido, M. R., Elwing, J. M., & Jose, A. (2025). Dual prostacyclin infusions: A case report of a patient symptom–driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae290

Vancouver

Stone JN, Kuebel DJ, Guido MR, Elwing JM, Jose A. Dual prostacyclin infusions: A case report of a patient symptom–driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxae290

BibTeX
@article{Stone2025,
  author = {Stone, Jessica N and Kuebel, Dalton J and Guido, Maria R and Elwing, Jean M and Jose, Arun},
  title = {Dual prostacyclin infusions: A case report of a patient symptom–driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxae290}
}
Kostenlos starten →